EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Neuroendocrine Tumors

Lisa Bodei, Vetri Sudar Jayaprakasam, Bernadette Zhi Ying Wong, Carina Mari Aparici

PET Clinics · 2024

DOI: 10.1016/j.cpet.2024.06.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PET Clinics, 2024. Verfasst von Lisa Bodei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, W…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Radiopharmaceuticals, Octreotide, Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Ipsen Biopharmaceuticals, Memorial Sloan-Kettering Cancer Center, Instituto Tecnológico Metropolitano.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptide receptor radionuclide therapy (PRRT) consists of administrating a radiolabeled octreotide derivative that targets somatostatin receptors present on the cell membrane of neuroendocrine tumor cells. Although PRRT was initially performed with 90Y-peptides, currently 177Lu-peptides represent the predominant form of treatment. PRRT results in significant tumor and symptomatic control in patients. Like with other available systemic therapies, responses are relatively short-lived. Several new peptides and strategies to improve the efficacy and tolerability of PRRT have been proposed. A critical step is individualizing treatments based on specific dosimetric estimates for the tumor and normal organs, and determining tissue radiosensitivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsRadiopharmaceuticalsOctreotideRadioisotopesHumansReceptors, SomatostatinBeta ParticlesReceptors, Peptide

Stichwörter der Autor:innen

(177)Lu-DOTATATEIndividualizationPeptide receptor radionuclide therapyTheranostics

Substanzen

RadiopharmaceuticalsOctreotideRadioisotopesReceptors, SomatostatinReceptors, Peptide

Autor:innen und Institutionen

  • Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Weill Cornell Medical College of Cornell University, New York, NY, USA.…
  • Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Weill Cornell Medical College of Cornell University, New York, NY, USA.
  • Department of Radiology, Weill Cornell Medical College of Cornell University, New York, NY, USA.
  • Division of Nuclear Medicine, Department of Radiology, University of Stanford, Stanford, CA, USA.

Förderung

  • Ipsen Biopharmaceuticals
  • Memorial Sloan-Kettering Cancer Center
  • Instituto Tecnológico Metropolitano

Zitieren

APA

Bodei, L., Jayaprakasam, V. S., Ying Wong, B. Z., & Aparici, C. M. (2024). Neuroendocrine Tumors. PET Clinics. https://doi.org/10.1016/j.cpet.2024.06.003

Vancouver

Bodei L, Jayaprakasam VS, Ying Wong BZ, Aparici CM. Neuroendocrine Tumors. PET Clinics. 2024. doi:10.1016/j.cpet.2024.06.003

BibTeX
@article{Bodei2024,
  author = {Bodei, Lisa and Jayaprakasam, Vetri Sudar and Ying Wong, Bernadette Zhi and Aparici, Carina Mari},
  title = {Neuroendocrine Tumors},
  journal = {PET Clinics},
  year = {2024},
  doi = {10.1016/j.cpet.2024.06.003}
}
Kostenlos starten →